Anthem Biosciences Limited (NSE:ANTHEM)
822.70
-23.25 (-2.75%)
At close: Aug 22, 2025, 3:30 PM IST
Anthem Biosciences Revenue
Anthem Biosciences had revenue of 5.40B INR in the quarter ending June 30, 2025, with 59.54% growth. This brings the company's revenue in the last twelve months to 20.52B, up 40.12% year-over-year. In the fiscal year ending March 31, 2025, Anthem Biosciences had annual revenue of 18.50B with 30.29% growth.
Revenue (ttm)
20.52B
Revenue Growth
+40.12%
P/S Ratio
22.52
Revenue / Employee
10.45M
Employees
1,825
Market Cap
462.15B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 18.50B | 4.30B | 30.29% |
Mar 31, 2024 | 14.20B | 3.62B | 34.24% |
Mar 31, 2023 | 10.58B | -1.83B | -14.74% |
Mar 31, 2022 | 12.41B | 1.35B | 12.24% |
Mar 31, 2021 | 11.05B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 537.77B |
Divi's Laboratories | 96.52B |
Cipla | 274.80B |
Apollo Hospitals Enterprise | 225.51B |
Mankind Pharma | 129.10B |
Zydus Lifesciences | 236.08B |
Fortis Healthcare | 80.94B |
Alkem Laboratories | 133.04B |